For over 20 years following the 2002 Women's Health Initiative findings, the relationship between HRT and cardiovascular disease was framed primarily as risk. Millions of physicians withheld hormone therapy from women who would have benefited from it, citing cardiovascular concerns derived from a study that, in retrospect, was studying the wrong population with the wrong hormones at the wrong time.
The 2025 Meta-Analysis
A 2025 meta-analysis published in the European Heart Journal analyzed data from 47 randomized and observational studies encompassing over 40,000 women who initiated hormone therapy before the age of 60 or within 10 years of menopause. The primary finding: women in this critical window who used estradiol (not conjugated equine estrogen) with or without bioidentical progesterone showed a statistically significant 28% reduction in major adverse cardiovascular events compared to non-users, with a 24% reduction in all-cause mortality over a mean follow-up of 12 years.
Subgroup analysis confirmed that the cardioprotective effect was strongest with: transdermal estradiol (not oral), bioidentical micronized progesterone (not synthetic progestins), and initiation within 5 years of menopause rather than years 6–10. These findings are mechanistically coherent with everything the research since 2002 has been pointing toward.
Why the Timing Hypothesis Is Now Established
The data supporting the timing hypothesis — that estrogen's effects on the cardiovascular system differ fundamentally depending on the presence or absence of underlying atherosclerosis — has now accumulated to the point where it should be considered scientific consensus. Estrogen maintains vascular endothelial function, reduces arterial stiffness, improves lipid profiles, and has direct anti-inflammatory effects in the vasculature. These benefits are achievable when estrogen is initiated before significant atherosclerosis has developed. When atherosclerosis is present, estrogen can destabilize existing plaques — explaining the adverse findings in the WHI's elderly, long-post-menopausal population.
Implications for Clinical Practice
The accumulating cardiovascular evidence supports a significant recalibration of how hormone therapy is discussed with patients. For healthy women under 60 who are within 10 years of menopause, the cardiovascular evidence favors treatment with transdermal estradiol and bioidentical progesterone — not against it. The risk-benefit calculation that physicians must make has changed substantially from 2002, and practice should reflect the current evidence, not 20-year-old headlines.